CN106957311A - Solvate of Raltitrexed and preparation method thereof - Google Patents
Solvate of Raltitrexed and preparation method thereof Download PDFInfo
- Publication number
- CN106957311A CN106957311A CN201611244886.XA CN201611244886A CN106957311A CN 106957311 A CN106957311 A CN 106957311A CN 201611244886 A CN201611244886 A CN 201611244886A CN 106957311 A CN106957311 A CN 106957311A
- Authority
- CN
- China
- Prior art keywords
- raltitrexed
- solvate
- water
- illustrative plates
- collection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
The invention discloses a kind of solvate of Raltitrexed, specifically related to Raltitrexed methanol hydrate II and Raltitrexed alcohol hydrate III, and disclose the preparation method of above two crystal formation, above two carries out having high stability, and it is the key intermediate for preparing Raltitrexed monohydrate.
Description
Technical field
The invention belongs to medicinal chemistry art, and in particular to a kind of solvation monohydrate of Raltitrexed and its preparation side
Method.
Background technology
Raltitrexed, is cooperated development with Zeneca by the cancer research administration of the Royal Marsden hospitals of Britain
Medicine.It is a kind of thymus gland synthetase inhibitors, belongs to the derivative of folic acid, for treating late period carcinoma of the colon and rectum patient.
Britain's Initial Public Offering in 1996, trade name Tomudex, its structural formula is as follows：
At this stage, reported seldom for Raltitrexed crystal formation, concentrated on for its preparation and process for purification
Open report.
Original grinds the process for purification that alkali-soluble acid analysis are disclosed in patent US4992550, has finally prepared a kind of powdered
Solid matter, is monohydrate crystal form, and there is provided 180-184 DEG C of relative melt points data.It is industrial at present also to use this mostly
The process for purification of alkali-soluble acid analysis is planted, but the preparation method easily causes the residual of sodium chloride in finished product.
One kind is disclosed in patent CN201210260633.7, CN201110361869.5 and CN201410844732.9
Raltitrexed is dissolved in the recrystallization method washed again after organic solvent, wherein, also carried in CN201210260633.7
Supply a kind of novel crystal forms of Raltitrexed, but the intermediate that is formed of above-mentioned process for purification is easily tacky or forms gel,
It is unfavorable for carrying out next step filtering technique.
The content of the invention
It is an object of the invention to provide a kind of solvate of Raltitrexed, its as refining reaction intermediate product,
For prepare high-purity Raltitrexed provide another path, the target product prepared by the process for purification, purity height, in length
It is obviously improved in terms of phase stability, improves the medicinal standard of Raltitrexed, and the process for refining is simple, is adapted to work
The big production of industryization.
The present invention provides a kind of solvated compoundses of Raltitrexed, it is characterised in that structure is as follows：
R=C1-C10 alkyl, wherein it is preferred that R is one kind in methyl, ethyl；
It is preferred that Raltitrexed methanol hydrate II, its X-ray powder diffraction figure 2 θ values be 7.9 ± 0.2 °, 10.2 ±
0.2°、12.9±0.2°、15.2±0.2°、17.0±0.2°°、20.4±0.2°、23.2±0.2°、24.00±0.2°、27.6
There is characteristic peak at ± 0.2 °.Preferably, 2 θ values 7.9 ± 0.2 °, 10.2 ± 0.2 °, 12.9 ± 0.2 °, 15.2 ± 0.2 °,
17.0±0.2°、18.9±0.2°、19.3±0.2°、20.4±0.2°、23.2±0.2°、24.00±0.2°、24.5±
There is characteristic peak at 0.2 °, 25.3 ± 0.2 °, 27.0 ± 0.2 °, 27.6 ± 0.2 °, 30.8 ± 0.2 °.It is highly preferred that XRPD schemes
Spectrum is shown in Fig. 1.
Its means of differential scanning calorimetry (DSC) curve of the Raltitrexed methanol hydrate II that the present invention is provided 48.2 DEG C, 98.2
DEG C, have endothermic peak at 178.5 DEG C, it loses solvent water molecules, 178.5 when losing solvent methanol molecule, 98.2 DEG C for 48.2 DEG C
DEG C to dissolve peak.DSC collection of illustrative plates refers to Fig. 2.
The present invention measures moisture 3.46% through karl Fischer Moisture Meter, about containing a molecular water.
Its thermogravimetric (TG) curve of the Raltitrexed methanol hydrate II that the present invention is provided has when being heated to 110 DEG C
9.5% weightlessness, is analyzed by Thermogravimetric Data and contains a hydrone and a methanol molecules in sub- Raltitrexed of getting a point.Thermogravimetric
Analysis chart is as shown in Figure 3.
Further, the present invention also provides the monocrystalline of Raltitrexed methanol hydrate II, it was demonstrated that a molecule thunder in its crystal formation II
Contain a molecular water and a molecule methanol for Qu Sai, its single crystal is received into single-crystal X-ray diffraction analysis, X single crystal diffraction figures
Spectrum such as Fig. 4, it is monoclinic system, axial length Crystal face angle α=90 °, β
=91.12 °, γ=90 °.
The present invention also provides Raltitrexed alcohol hydrate III, its X-ray powder diffraction figure 2 θ values be 7.7 ± 0.2 °,
10.1±0.2°、12.7±0.2°、14.9±0.2°、16.7±0.2°、19.0±0.2°、20.3±0.2°、22.9±0.2°、
There is characteristic peak at 23.8 ± 0.2 °, 24.0 ± 0.2 °, 27.2 ± 0.2 °.Preferably, 2 θ values 7.7 ± 0.2 °, 8.1 ±
0.2°、10.1±0.2°、10.4±0.2°、10.8±0.2°、12.7±0.2°、13.2±0.2°、14.9±0.2°、16.7±
0.2°、17.5±0.2°、19.0±0.2°、19.8±0.2°、20.3±0.2°、22.9±0.2°、23.8±0.2°、24.0±
There is characteristic peak at 0.2 °, 27.2 ± 0.2 °, 30.6 ± 0.2 °, 32.5 ± 0.2 °.It is highly preferred that XRPD collection of illustrative plates is shown in Fig. 5.
The present invention provide its differential scanning calorimetry (DSC) curve of Raltitrexed alcohol hydrate III 50.0 DEG C, 98.2
DEG C, have endothermic peak at 173.5 DEG C, lose solvent water molecules, 173.5 DEG C when losing etoh solvent molecule, 98.2 DEG C for 50.0 DEG C
To dissolve peak.DSC collection of illustrative plates is shown in Fig. 6.
The present invention measures moisture 3.50% through karl Fischer Moisture Meter, about containing a molecular water.
Its thermogravimetric (TG) curve of the Raltitrexed alcohol hydrate III that the present invention is provided has when being heated to 140 DEG C
12.33% weightlessness, is analyzed by Thermogravimetric Data and contains a hydrone and an ethanol molecule in sub- Raltitrexed of getting a point.Heat
Weight analysis figure is as shown in Figure 7.
On the other hand, present invention also offers the preparation method of Raltitrexed methanol hydrate II, comprise the following steps：Will
Raltitrexed is dissolved in the mixed system of water and methanol solvate, and heating for dissolving, heat is taken out, slow cooling, and add water precipitation, separation,
It is drying to obtain.Wherein, the volume ratio of water and methanol solvate is 1：1~1：6.
On the other hand, present invention also offers the preparation method of Raltitrexed alcohol hydrate III, comprise the following steps：Will
Raltitrexed is dissolved in the mixed system of water and alcohol solvent, and heating for dissolving, heat is taken out, slow cooling, and add water precipitation, separation,
It is drying to obtain.Wherein, the volume ratio of water and alcohol solvent is 1：3~1：7.
Because Raltitrexed powder is insoluble in water, generally, water is added in organic solvent, can make the dissolving of crude product
Degree reduction, this is also that anhydrous alcohols or ether are used in documents CN201210260633.7, CN201110361869.5
The reason for class solvent dissolves to Raltitrexed crude product, but inventor has surprisingly found that and certain ratio is added in alcohols solvent
The solubility of Raltitrexed can be obviously improved on the contrary after the water of example, and whether the ratio of water and alcohols solvent is to that can obtain solid-state
Intermediate is also most important.
Influence of the ratio of water and alcohol to Raltitrexed crystal formation and the shadow to its solubility are verified below by way of experiment
Ring, the experiment is variant outer in the ratio of water removal and alcohol, carries out in the case of other experimental condition all sames, specific test result
Refer to following table.
Summary of the table 1 from pilot-line crystalline results
It has also been found that using Raltitrexed solvate II, III as intermediate, preparing Raltitrexed monohydrate
Method, pure Raltitrexed monohydrate can be prepared by this method substantially, and the monohydrate prepared by this method exists
In experiment for long-term stability, more stable characteristic is shown.
The following is the result of small-scale stability test, Raltitrexed crude product can be used with N- [5- (N- methylaminos) -2- thiophenes
Fen formoxyl]-Pidolidone diethylester and 2- methyl -6- bromomethyls -3- hydrogen-quinazoline-4-one be raw material, through condensation, hydrolysis
It is prepared into purchase Raltitrexed crude product, purity about 95%, moisture 3% at Raltitrexed crude product or market.
Batch 1：Raltitrexed monohydrate is prepared according to the method progress disclosed in US4992550 (referred to as ' 550)；
Batch 2：By Raltitrexed crude product, recrystallization generation Raltitrexed methanol hydrate II, vacuum is done at 40-60 DEG C
Dry 6-8h, obtains Raltitrexed monohydrate.
Batch 3：By Raltitrexed crude product, recrystallization generation Raltitrexed alcohol hydrate III, vacuum is done at 50-65 DEG C
Dry 6-8h, obtains Raltitrexed monohydrate.
Analysis is compared to ' 550 methods and the present processes below, its specific difference refers to following table
The process for purification comparative analysis of table 2
As can be seen that this process for purification is with ' directly avoiding NaCl productions compared with the method disclosed in 550 from above-mentioned table
It is raw, and chlorion it is exceeded be the variety production quality control difficult point.Therefore the present invention is simple to operate, is more suitable for industrialization behaviour
Make.
At the same time, the method prepared according to the application with ' disclosed in 550 compared with preparation method, obtained finished product it is steady
It is qualitative higher, above-mentioned conclusion is verified below by way of stability test.
By the product of above-mentioned 3 batches, the study on the stability of progress 30 days, experimental condition in the case of constant temperature and humidity：60
DEG C/92.5% relative humidity (RH), and under conditions of illumination 4000lx, place 10 days, respectively at 0 day, 5 days, 10 days, sampling,
Carry out product purity and foreign impurity matters test.
The result of the batch 1-3 of table 3 stability test
From data above, using solvate as intermediate, convection drying obtains the water of Raltitrexed one of highly finished product preparation
Compound, it is even better in long-time stability.
Brief description of the drawings
The XRPD collection of illustrative plates of Fig. 1 Raltitrexed methanol hydrate II；
The DSC collection of illustrative plates of Fig. 2 Raltitrexed methanol hydrate II；
The TGA collection of illustrative plates of Fig. 3 Raltitrexed methanol hydrate II；
The monocrystalline space structure figure of Fig. 4 Raltitrexed methanol hydrate II；
The XRPD collection of illustrative plates of Fig. 5 Raltitrexeds alcohol hydrate III；
The DSC collection of illustrative plates of Fig. 6 Raltitrexeds alcohol hydrate III；
The TGA collection of illustrative plates of Fig. 7 Raltitrexeds alcohol hydrate III；
The unformed XRPD collection of illustrative plates of Fig. 8 Raltitrexeds；
The HPLC collection of illustrative plates of Raltitrexed monohydrate prepared by Fig. 9 embodiments 9；
The HPLC collection of illustrative plates of Raltitrexed monohydrate prepared by Figure 10 embodiments 10.
Embodiment
Technical scheme is further illustrated with reference to specific embodiment, but does not limit the present invention.
Raltitrexed crude product can be used with N- [5- (N- methylaminos) -2- Thenoyls]-Pidolidone diethylesters and 2-
Methyl -6- bromomethyls -3- hydrogen-quinazoline-4-one is raw material, is prepared at Raltitrexed crude product or market and purchases through condensation, hydrolysis
Buy Raltitrexed crude product, purity about 95.0%, moisture 3%.
The instrument of present invention detection drug crystal forms structure and its performance is as follows：
1. mono-crystalline structures are determined by X-ray single crystal diffractometer, Holland of manufacturer Enraf Noius＆Enraf Noius are public
Department, INSTRUMENT MODEL：CAD4/PC.
2. powder diffractometer is produced by Arl Inc. of Switzerland of manufacturer, INSTRUMENT MODEL：X'TRA, Cu-K αTube voltage 40KV, tube current 30mA, 8 °/min of sweep speed.
3. differential scanning calorimetric curve and thermogravimetric curve are produced by PerKinElmer companies of the U.S., INSTRUMENT MODEL：Pyris
1DSC, using nitrogen atmosphere, 10 DEG C/min of heating rate.
4. karl Fischer moisture tester model：Mettler Toledo V30Volumetric KF Titrator
Embodiment 1 prepares the powder of Raltitrexed methanol monohydrate II
In the mixed solvent that 1g Raltitrexeds are dissolved in 40ml methanol and 10ml water, 50 DEG C of dissolved clarifications are heated to, heat is taken out,
Natural slow cooling has crystal precipitation to 35 DEG C, and water 110ml is slowly added dropwise, and 5 DEG C of crystallization 2h of low temperature, filtration drying produces crystal formation
II white green crystal powder.It is characterized with XRPD, DSC, TG, as a result such as Fig. 1~3.
Embodiment 2 prepares the monocrystalline of Raltitrexed methanol monohydrate II
1g Raltitrexed powder is dissolved in water：Methanol (volume ratio=1：3) in mixed solvent, 0.45 μm of filter paper is passed through
Undissolved solid is filtered out, obtained saturation filtrate is sealed with the film for pricking hole, solid precipitation, mistake is slowly evaporated into
Filter, vacuum drying collects solid and produces crystal formation II.X-ray single crystal diffraction is carried out to single crystal, as a result such as Fig. 4.
Embodiment 3 prepares the powder of Raltitrexed ethanol monohydrate III
In the mixed solvent that 1g Raltitrexeds are dissolved in 60ml ethanol and 10ml water, 50 DEG C of dissolved clarifications are heated to, heat is taken out,
Natural slow cooling adds the crystal seed of Raltitrexed ethanol monohydrate III, has crystal precipitation, be naturally cooling to 35 DEG C to 40 DEG C,
Water 170ml is slowly added dropwise, 5 DEG C of crystallization 2h of low temperature, filtration drying produces the crystal powder of crystal formation III.
Prepared in the pure organic solvent of embodiment 4 amorphous
1g Raltitrexeds are dissolved in 40ml methanol, 50 DEG C of dissolved clarifications are heated to, heat is taken out, natural slow cooling to 35 DEG C,
There is crystal precipitation, water 110ml is slowly added dropwise, 5 DEG C of crystallization 2h of low temperature, filtration drying produces yellowish green powder, and its XRD powder diffraction is such as
It is amorphous shown in Fig. 8.
Embodiment 5 is prepared according to the method disclosed in CN201110001785.0
By 0.20g (0.38mmol) N- [5- [N- [(3,4- dihydro -2- methyl -4- oxo -6- quinazolyls) methyl]-N-
Methylamino] -2- thenoyls]-Pidolidone diethylester is dissolved in 10mL ethanol and 10mL acetone, adds 3molL-1 hydrogen
Aqueous solution of sodium oxide 14mL, is stirred at room temperature reaction 3h.Ethanol and acetone is evaporated off in vacuum distillation, and pH=is adjusted with 2molL-1 hydrochloric acid
4, filtering obtains yellow-brown solid, is recrystallized with methanol-absolute ether, obtains light yellow solid Raltitrexed 0.14g, yield
80.1%.It is amorphous powder after testing.
Embodiment 6 is prepared according to the method disclosed in CN201210260633.7
Temperature is 0 DEG C, is added into 480ml 1N NaOH solutions and adds 52.8g N- [5- [N- methyl-N- (2- first by several times
Base -4- oxo -3,4- dihydroquinazoline base -6- methyl) amino] thiophene -2- formoxyls]-Pidolidone diethylester is (about
0.1mol) purity continues to stir 2 hours, filtering 97%.It is miscellaneous that filtrate falls organic phase with dichloromethane (500ml × 2) extraction
Matter, then remaining organic phase impurity is extracted again with ethyl acetate (500ml × 2), under agitation (0--5 DEG C) water layer 1N salt
Acid adjusts pH value to 3.0 or so, has a large amount of solids to separate out.Stirred 1 hour at 0 DEG C, filtering, product purifying water washing is washed till filter
Liquid is without Cl-Ion residues are determined with 0.1NAgNO3), drain as far as possible, obtain 138 grams of the thick wet product of Raltitrexed, take the Raltitrexed thick
Product 13.8g is added in 600ml absolute methanols, is stirred at room temperature 0.5 hour, preproduction has a small amount of insoluble matter, filters at room temperature,
Crystallization is concentrated at 28-35 DEG C of filtrate, puts in 4 DEG C of refrigerators and refrigerates 3 hours, filtering, product a small amount of purifying water washing, room temperature in vacuo
Dry 10 hours, obtain the crystalline solid 3.2g of several near-whites, it is unformed powder after testing.
Embodiment 7 is prepared according to the method disclosed in CN201410844732.9
5g Raltitrexed crude products are added into reaction bulb, 15ml methanol are added, heating water bath, return stirring makes its complete
Portion is dissolved, and flowed back 0.5h, and solution is cooled into 40 DEG C, is stood 1h in 40 DEG C of insulations, is crossed and filter to remove impurity, then solution is small 4
When interior slow cooling to 15 DEG C, be incubated 7h, solid separate out.It is amorphous powder after testing.
Embodiment 8 is prepared according to the method disclosed in CN20110361869.5
Crude product is placed in 1000ml reaction bulbs, is added 600ml methanol and is heated to reflux to clarification, filtering, filtrate is cooled to 5-
10 DEG C, about 4200ml purified water stirring and crystallizings are slowly added into, are filtered, solid purifying water washing obtains faint yellow solid.40 DEG C true
Sky is dried 24 hours, obtains light yellow fine work 30.3g, molar yield 85%.HPLC purity 99.8%.It is amorphous powder after testing
End.
Embodiment 9 carries out experiment for long-term stability investigation to unformed, monohydrate, solvated compoundses.
By Raltitrexed is unformed, monohydrate, solvate II, III stabilization of 6 months is carried out in climatic chamber
Property experiment.Experimental condition is：25 DEG C/75% relative humidity (RH), was sampled respectively at 0,1,2,3,6 months, carried out purity and miscellaneous
Quality inspection is tested.
The different crystal forms stability test result of table 4
Knowable to upper table data, the methanol hydrate and alcohol hydrate of Raltitrexed in long-term stable experiment,
Show than unformed higher stability, and its stability is not inferior to the stability of monohydrate.
Embodiment 10
The gained Raltitrexed methanol hydrate 2g of Example 1, thunder is produced after being dried in vacuo 6-8 hours at 40-60 DEG C
Monohydrate is filled in for song, yield is 86%, its purity is 99.94%, maximum single miscellaneous 0.04%, its HPLC collection of illustrative plates refers to Fig. 9.
Embodiment 11
The gained Raltitrexed alcohol hydrate 3g of Example 3, is dried in vacuo after 6-8h at 50-65 DEG C, produces thunder and replace
Song plug monohydrate, yield is 83%, and purity is 99.84%, and miscellaneous maximum list is 0.06%, and its HPLC collection of illustrative plates refers to Figure 10.
Claims (10)
1. a kind of solvated compoundses of Raltitrexed, it is characterised in that structure is as follows：
Wherein R=C1-C10 alkyl.
2. the solvate of a kind of Raltitrexed according to claim 1, it is characterised in that R is one in methyl, ethyl
Kind.
3. the solvate of a kind of Raltitrexed according to claim 1, it is characterised in that it is Raltitrexed methanol one
Hydrate II, its X-ray powder diffraction figure 2 θ values be 7.9 ± 0.2 °, 10.2 ± 0.2 °, 12.9 ± 0.2 °, 15.2 ± 0.2 °,
There is characteristic peak at 17.0 ± 0.2 ° °, 20.4 ± 0.2 °, 23.2 ± 0.2 °, 24.00 ± 0.2 °, 27.6 ± 0.2 °.
4. a kind of solvate of Raltitrexed according to claim 3, it is characterised in that its X-ray powder diffraction figure
2 θ values 7.9 ± 0.2 °, 10.2 ± 0.2 °, 12.9 ± 0.2 °, 15.2 ± 0.2 °, 17.0 ± 0.2 °, 18.9 ± 0.2 °, 19.3
±0.2°、20.4±0.2°、23.2±0.2°、24.00±0.2°、24.5±0.2°、25.3±0.2°、27.0±0.2°、
There is characteristic peak at 27.6 ± 0.2 °, 30.8 ± 0.2 °, it is highly preferred that XRPD collection of illustrative plates is shown in Fig. 1, its differential scanning calorimetry
(DSC) curve has endothermic peak at 48.2 DEG C, 98.2 DEG C, 178.5 DEG C, and DSC collection of illustrative plates refers to Fig. 2, and TGA collection of illustrative plates refers to Fig. 3.
5. the solvate of a kind of Raltitrexed according to claim 3, it is characterised in that it is monoclinic system, axial lengthCrystal face angle α=90 °, β=91.12 °, γ=90 °, X is mono-
Brilliant diffracting spectrum is as shown in Figure 4.
6. a kind of preparation method of the solvated compoundses of Raltitrexed according to claim 3-5, it is characterised in that including
Following steps：In the mixed system that Raltitrexed is dissolved in water and methanol solvate, heating for dissolving, heat is taken out, and slow cooling adds water
Separate out, separation is drying to obtain, wherein, the volume ratio of water and methanol solvate is 1：1~1：6.
7. the solvate of a kind of Raltitrexed according to claim 1, it is characterised in that it is Raltitrexed ethanol one
Hydrate III, its X-ray powder diffraction figure 2 θ values be 7.7 ± 0.2 °, 10.1 ± 0.2 °, 12.7 ± 0.2 °, 14.9 ± 0.2 °,
16.7±0.2°、19.0±0.2°、20.3±0.2°、22.9±0.2°、23.8±0.2°、24.0±0.2°、27.2±0.2°
Place has characteristic peak.
8. a kind of solvated compoundses of Raltitrexed according to claim 7, it is characterised in that X-ray powder diffraction figure
2 θ values be 7.7 ± 0.2 °, 8.1 ± 0.2 °, 10.1 ± 0.2 °, 10.4 ± 0.2 °, 10.8 ± 0.2 °, 12.7 ± 0.2 °, 13.2
±0.2°、14.9±0.2°、16.7±0.2°、17.5±0.2°、19.0±0.2°、19.8±0.2°、20.3±0.2°、22.9
There is characteristic peak, more at ± 0.2 °, 23.8 ± 0.2 °, 24.0 ± 0.2 °, 27.2 ± 0.2 °, 30.6 ± 0.2 °, 32.5 ± 0.2 °
Preferably, XRPD collection of illustrative plates is shown in Fig. 5, and its differential scanning calorimetry (DSC) curve has heat absorption at 50.0 DEG C, 98.2 DEG C, 173.5 DEG C
Peak, DSC collection of illustrative plates refers to Fig. 6, and TGA collection of illustrative plates refers to Fig. 7.
9. a kind of preparation method of the solvate of Raltitrexed according to claim 7-8, it is characterised in that including with
Lower step：In the mixed system that Raltitrexed is dissolved in water and alcohol solvent, heating for dissolving, heat is taken out, slow cooling, and add water analysis
Go out, separate, be drying to obtain, wherein, the volume ratio of water and alcohol solvent is 1：3~1：7.
10. a kind of solvate of Raltitrexed according to claim 1-9, it is as preparing Raltitrexed hydrate
Purposes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611244886.XA CN106957311B (en) | 2016-12-29 | 2016-12-29 | Solvate of raltitrexed and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611244886.XA CN106957311B (en) | 2016-12-29 | 2016-12-29 | Solvate of raltitrexed and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106957311A true CN106957311A (en) | 2017-07-18 |
| CN106957311B CN106957311B (en) | 2020-03-31 |
Family
ID=59481574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611244886.XA Active CN106957311B (en) | 2016-12-29 | 2016-12-29 | Solvate of raltitrexed and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106957311B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4992550A (en) * | 1986-03-27 | 1991-02-12 | Imperial Chemical Industries Plc | Anti-tumour agents |
| CN103570702A (en) * | 2012-07-26 | 2014-02-12 | 南京优科生物医药有限公司 | Method for industrial preparation of raltitrexed and novel raltitrexed crystal form for pharmacy |
| CN104447724A (en) * | 2014-12-31 | 2015-03-25 | 四川峨嵋山药业股份有限公司 | Refining method of raltitrexed |
| CN105111197A (en) * | 2015-08-26 | 2015-12-02 | 上海鼎雅药物化学科技有限公司 | Synthesis methods of raltitrexed |
-
2016
- 2016-12-29 CN CN201611244886.XA patent/CN106957311B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4992550A (en) * | 1986-03-27 | 1991-02-12 | Imperial Chemical Industries Plc | Anti-tumour agents |
| CN103570702A (en) * | 2012-07-26 | 2014-02-12 | 南京优科生物医药有限公司 | Method for industrial preparation of raltitrexed and novel raltitrexed crystal form for pharmacy |
| CN104447724A (en) * | 2014-12-31 | 2015-03-25 | 四川峨嵋山药业股份有限公司 | Refining method of raltitrexed |
| CN105111197A (en) * | 2015-08-26 | 2015-12-02 | 上海鼎雅药物化学科技有限公司 | Synthesis methods of raltitrexed |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106957311B (en) | 2020-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3337485B1 (en) | Crystalline forms of ibrutinib | |
| BR112016010788B1 (en) | PROCESS FOR THE LARGE-SCALE PRODUCTION OF 1-[(2-BROMOPHENYL)SULFONYL]-5-METHOXY-3-[(4-METHYL-1-PIPERAZINYL)METHYL]-1H-INDOLE | |
| US20090076272A1 (en) | Polymorphs of eszopiclone malate | |
| US20180065958A1 (en) | Preparation method of pci-32765 crystal form a | |
| CN114746412A (en) | Novel crystal form of KD-025 and preparation method thereof | |
| CN107531744A (en) | A kind of new crystalline form of shellfish cholic acid difficult to understand and preparation method thereof | |
| CN106957311A (en) | Solvate of Raltitrexed and preparation method thereof | |
| JP4681545B2 (en) | Method for producing crystalline polymorphs of platelet aggregation inhibitors | |
| JP2013527239A (en) | Ixabepilone solid form | |
| CN108570045B (en) | Crystal form of anisodamine hydrobromide, preparation method and pharmaceutical composition thereof | |
| US8343991B2 (en) | Anhydrous crystalline vinflunine salts, method of preparation and use thereof as a drug and means of vinflunine purification | |
| CN106957312B (en) | Raltitrexed hydrate crystal forms and preparation method thereof | |
| CN108659038B (en) | Polymorphic substance of 1-stearoyl-2-valoyl-sn-glycerol-3-phosphatidylcholine and preparation method thereof | |
| CN108659037B (en) | Polymorphic substance of valproic acid phospholipid derivative and preparation method thereof | |
| CN110776519A (en) | Preparation method of clopidogrel hydrogen sulfate crystal form II | |
| CN115043816B (en) | Chiral resolution method of selenium octanoic acid | |
| US9834540B2 (en) | Omeprazole Sodium semihydrate and preparation method thereof | |
| CN105753820B (en) | A kind of method of purification of dehydroandrographolide succinate | |
| TW202227387A (en) | Treprostinil monohydrate crystals and methods for preparation thereof | |
| EP4215540A1 (en) | Method for mass-producing sodium taurodeoxycholate | |
| WO2022262841A1 (en) | Salt form and crystal form of spiro compound and preparation method therefor | |
| WO2015123801A1 (en) | Preparation method for polymorphic 6-(4-chlorophenoxy)-tetrazolo[5,1-a]phthalazine and use thereof | |
| CN117466914A (en) | Novel crystal form of balo Sha Weizhi and method for purifying products by using novel crystal form | |
| CN113801182A (en) | Azacitidine crystal form D | |
| CN116239538A (en) | New lopinavir crystal form and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |